{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022715","form_type":"8-K","ticker":"VYCO","cik":"0001424768","company_name":"VYCOR MEDICAL INC","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.958053+00:00","generated_at":"2026-05-17T16:15:54.568725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vycor Medical Q2 revenue up 22% to $496K; VBAS division drives growth with new international distribution","bullets":["Q2 total revenue $496,353 (+22% YoY); Vycor Medical (VBAS) up 24% to $481,788, led by international markets.","GAAP operating profit Q2 $51,146; non-GAAP operating profit $84,481, up from $31,859 in Q2 2024.","Gross margin fell to 83% from 91% due to validation/shipping costs of new production and sales mix.","Entered new distribution agreements for France and Spain during H1 2025, targeting key international markets.","Two new peer-reviewed VBAS clinical papers published in Q2; total now 48. NovaVision study validates NeuroEyeCoach for home/clinic."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022715","json":"https://secwatch.observer/filing/0001641172-25-022715.json","markdown":"https://secwatch.observer/filing/0001641172-25-022715.md","text":"https://secwatch.observer/filing/0001641172-25-022715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1424768/000164117225022715/0001641172-25-022715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1424768/000164117225022715/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:15:54.568725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}